Spotlights on Virus Pathogenesis Human Immunity Interactivity
DOI:
https://doi.org/10.33687/ricosbiol.01.01.0014Keywords:
COVID-19, COVID-19 immunity, interleukin storm, pathogenesis, SARS-CoV2Abstract
A novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV- 2) causes COVID-19; a newly emerged global pandemic disease and found to be more infective and more pathogenic than former human respiratory corona viruses due to its higher specific receptor binding affinity. Exposed COVID-19 data clearly recognize that the human immune response to SARS-CoV-2 is the prime factor affecting the course of disease. This article places emphasis on virus pathogenesis, host cell interaction, immunological response for COVID-19 trying to light on the obscured areas of this novel human health menace.
Downloads
References
1.WHO,https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---14-december-2022.
2.V’kovski P., Kratzel A., Steiner S., Stalder H., Thiel V. (2021). Coronavirus Biology and Replication: Implications for SARS-CoV-2. Nat. Rev. Microbiol. 19, 155–170.
3.XuZ,ShiL,WangY,etal,(2020).Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lance tRespir Med, 8(4):420-422.
4.ZhouY,FuB,ZhengX,etal,(2020).PathogenicTcells and inflammatory monocytes incite inflammatorystorm in severe COVID-19 patients. Natl. Sci. Rev., 13:(3): nwaa041.
5.Balkhi MY. Mechanistic understanding of innate and adaptive immune responses in SARS-CoV-2 infection. Mol Immunol. 2021 Jul; 135, 268-275.
6.Yu S, Gang W, Xiao P, et al, (2020). An overview ofCOVID-19.J Zhejiang Univ SciB, 21(5):343–360.
7.WichmannD,Jan-PeterS,MarcL,et al (2020). Autopsy Findings and Venous Thromboembolism in Patients With COVID-19 A Prospective Cohort Study. Ann. Intern. Med, 6,M20-2003.
8.Letko MC and Munster V.,(2020). Functional assessment of cell entry and receptor usage for lineage B β-coronaviruses, including 2019-nCoV.bio Rxiv.
9.Lan J, Ge J, Yu J, et al, (2020). Structure of the SARS-CoV-2spike receptor-binding domain bound to the ACE2 receptor. Nature, 581:215–220.
10.Mousavizadeh L and Ghasemi S, (2020). Genotype and phenotype of COVID-19: Their roles in pathogenesis. J. Microbiol. Immunol. Infect, 2020Mar31.
11. Xia S, Liu M, Wang C, et al, (2020). Inhibition of SARS-CoV-2 (previously 2019 nCoV) infection by a highly potentpan - corona virus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. Cell research, 30(4): 343-355.
12.Coutard B, Valle C, de Lamballerie X, et al, (2020). The spike glycoprotein of the new coronavirus 2019-n Co Vcontains a furin-like cleavage site absent in CoV of the same clade.Antiviral research, 176, 104742.
13.Walls A C,Park Y J,Tortorici M A, et al ,(2020). Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell, 181(2):281-292.e6.
14.Nikolich-Zugich J, Knox KS, Rios CT, et al, (2020). SARS-CoV-2 and COVID-19 in older adults: what wemay expect regarding pathogenesis, immune responses, and outcomes. GeroScience, 1-10.
15.Prompetchara E, Ketloy C, and Palaga T, (2020). ImmuneresponsesinCOVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pac JAllergy Immunol, 38(1): 1-9.
16.Rajaei S and Dabbagh A,(2020). The immunologicbasisofCOVID-19: a clinical approach. Journal of Cellular& Molecular Anesthesia, 5(1): 37-42.
17.Vabret N, Graham J, Britton CG, et al, ( 2020), Review, Immunology of COVID-19: Current State of the Science. Immunity 52(6-16): 910-941.
18.Mantlo E K, Bukreyeva N, Maruyama J, et al, (2020). Antiviral Activities of Type I Interferons to SARS-CoV-2 Infection. Antiviral Res, 179: 104811.
19.Zhao J, Zhao J, and Perlman ST, (2010). Cell responses are required for protection from clinical disease and for virus clearance insevere acute respiratory syndrome coronavirus-infected mice.J Virol, 84:9318–9325.
20.Channappanavar R, Zhao J, and Perlman ST, (2014).Cell-Mediated Immune Response to Respiratory Corona viruses. Immunol Res,59(1-3):118-28.
21.Chen J, Lau YF, Lamirande EW, et al, (2010). Cellularimmune responses to severe acute respiratory syndrome corona virus (SARS-CoV) infection in senescent BALB/c mice: CD4+ T cells are important in control ofSARS-CoV infection. J Virol, 84:1289–1301
.22.van den Brink EN, TerMeulen J, Cox F, et al, (2005). Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus. J Virol, 79:1635–1644.
23.Wrapp D, Wang N, Corbett KS, et al, (2020). Cryo-EM structure of the 2019-n CoV spike in the prefusion conformation. Science, 367:1260–1263.
24.Yan R, Zhang Y, Li Y, et al, (2020). Structural basis for the recognition of the SARS-CoV -2 by full-length human ACE2. Science,6485:420–2.
25.Tian X, Li C, Huang A, etal, (2020). Potent binding of 2019 novel corona virus spike protein by a SARS corona virus- specific Human monoclonal antibody. Bio. Rxiv., 9:382–5.
26.Ter Meulen J, van den Brink E N, Poon L L, etal,(2006). Human monoclonal antibody combination against SARS corona virus: synergy and coverage of escape mutants. PLoS Med,3:e237.
27.Wang C,Li W, Drabe k D,et al,(2020).A human monoclonal antibody blocking SARS-CoV-2 infection. Bio Rxiv.
28.Huang C, Wang Y, Li X, et al, (2020). Clinical features of patients infected with 2019 nove lcorona virus in Wuhan, China. The lancet, 395(10223): 497-506.
29.Yang X, Dai T, Zhou X, etal, (2020).Analysis of adaptive immune cell populations and phenotypes in the patients infected by SARS-CoV-2 .med Rxiv. https://doi.org/10.1101/2020.03.23. 20040675.
30. Frieman M and Baric R, (2008). Mechanisms of Severe Acute Respiratory Syndrome Pathogenesis and Innate Immunomodulation. Microbiol Mol Biol Rev, 72(4):672–685.
31. Zielecki F, Weber M, Eickmann M, et al, (2013). Human cell tropism and innate immune system interactions of human respiratory coronavirus EMC compared to those of severe acute respiratory syndrome coronavirus. J Virol,87(9):5300-4.
32.Fehr A R, Channappanavar R, and Jankevicius G,(2016). Th eConserved Corona viru sMacro-Domain Promotes Virulence and Suppresses the Innate Immune Response during Severe Acute Respiratory SyndromeCoronavirus Infection.mBio. 13:7(6).
33.Li X, Geng M, Peng Y, et al, (2020). Molecular immunepathogenesis and diagnosis of COVID-19. Journal of Pharmaceutical Analysis, 10(2):102-108.
34.Solana R, Pawelec G, and Tarazona R, (2006). Agingand innateimmunity. Immunity, 24:491–494.35. Goronzy J J, Li G, Yu M, etal, (2012).Signaling pathways in aged T cells are flection of T cell differentiation, cell senescence and host environment. Semin Immunol, 24:365–72.
36.Zheng J, Miao J, Guo R, Guo J, Fan Z, Kong X, Gao R, Yang L. Mechanism of COVID-19 Causing ARDS: Exploring the Possibility of Preventing and Treating SARS-CoV-2. Front Cell Infect Microbiol. 2022 Jun 14; 12:931061.
37.Kogut I, Scholz JL, Cancro MP, et al, (2012). B cel lmaintenance and function in aging. Semin Immunol, 24:342–349.38.Chinn IK, Blackburn CC, Manley NR, et al, (2012).Changes in primary lymphoid organs with aging. SeminImmunol, 24:309–320.
39.Naylor K, Li G, Vallejo AN, et al, (2005). The influence of age on T cell generation and TCR diversity. J Immunol, 174:7446–7452.
40.Thompson H L, Smithey M J, Surh C D, et al, (2017).Functional and homeostatic impact of age - related changes in lymph node stroma. Front Immunol, 8:706.
41.Richner JM, Gmyrek GB, Govero J, et al, (2015). Age-dependent cell trafficking defects in draining lymph nodes impair adaptive immunity and control of WestNileVirus infection. PLoS Pathog,11:e1005027.
42.Metcalf TU, Cubas RA, Ghneim K, et al, (2015). Globalanalyse srevealedage -related alterations in innate immune response safter stimulation of pathogen recognition receptors. Aging Cell, 14:421–432.
Downloads
Published
Data Availability Statement
RBJ
Issue
Section
Categories
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/ by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http:// creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
